Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: Response to chemotherapy and octreotide LAR (328 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2005 Apr; 28(4): 371-378.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 1.496, 5-year impact factor: 1.273
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-23344454963&partnerID=40&md5=984ec2eb70e02d812cc69aa5a2a25691
Keywords: Nse, Octreoscan, Octreotide Lar, Ovarian Carcinoma, Poorly Differentiated Neuroendocrine Carcinoma, Thyroid Carcinoma, Cisplatin, Etoposide, Antineoplastic Agent, Antineoplastic Hormone Agonists And Antagonists, Article, Case Report, Clinical Feature, Dyspnea, Endocrine Gland, Female, Goiter, Histology, Human, Human Tissue, Immunohistochemistry, Liver Metastasis, Liver Polycystic Disease, Lymph Node, Neuroendocrine Tumor, Pericardium, Small Cell Carcinoma, Thyroid Nodule, Trachea Muscle, Tumor Differentiation, Tumor Localization, Adrenal Tumor, Liver Tumor, Lymph Node Metastasis, Ovary Tumor, Pathology, Treatment Outcome, Adrenal Gland Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Liver Neoplasms, Lymphatic Metastasis, Unknown Primary, Ovarian Neoplasms,
Affiliations:
*** IBB - CNR ***
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
Department of Anatomical Pathology and Cytology, Federico II University of Naples, Naples, Italy
Department of Biomorphological and Functional Sciences, Federico II University of Naples, Naples, Italy
References:
Kulke, M.H., Mayer, R.J., Carcinoid tumors (1999) N Engl J Med, 340, pp. 858-86
Modlin, I.M., Sandor, A., An analysis of 8305 cases of carcinoid tumors (1997) Cancer, 79, pp. 813-818
Levi, F., Te, V.C., Randimbision, L., Rindi, G., La Vecchia, C., Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97 (2000) Br J Cancer, 83, pp. 952-955
Soga, J., Statistical evaluation of 2001 carcinoid cases with metastases, collected from literature: A comparative study between ordinary carcinoids and atypical varieties (1998) J Exp Clin Cancer Res, 17, pp. 3-12
Götrtz, B., Roth, J., Krahenmann, A., Mutations and allelic deletions of the MEN 1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms (1999) Am J Pathol, 154, pp. 429-436
Lohmann, D., Putz, B., Reich, U., Bohm, J., Prauer, H., Hofler, H., Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data (1993) Am J Pathol, 142, pp. 907-915
Muligan, L.M., Kwok, J.B., Healey, C.S., Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (1993) Nature, 363, pp. 458-460
Vortmeyer, A.O., Lubensky, I.A., Erino, M.J., Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas (1997) J Nat Cancer Lnst, 89, pp. 1448-1453
Solda, E., Cappella, C., Fiocca, R., Sessa, F., La Rosa, S., Rindi, G., Disorders of the endocrine system (1998) Pathology of the Gastrointestinal Tract, HGSC Ming, pp. 295-322. , Williams & Wilkins eds. Philadelphia
Solcia, E., Klöppel, G., Sobin, L.H., World Health Organization International Histological Classification of tumors (2000) Histological Typing of Neuroendocrine Tumors. 2nd Ed, pp. 1-5. , Berlin, Heidelberg: Springer-Verlag
Mitry, E., Rougier, R., The treatment of undifferentiated neuroendocrine tumors (2001) Crit Rev Oncol Hematol, 37, pp. 47-51
Ardill, J.E.S., Erikkson, B., The importance of the measurement of circulationg markers in patients with neuroendocrine tumors of the pancreas and gut (2003) Endocr Relat Cancer, 10, pp. 459-462
Caplin, M., Wiedenmann, B., The management of patients with neuroendocrine tumors (2003) Endocr Relat Cancer, 10, pp. 425-426
Kaltsas, G.A., Mukherjee, J.J., Gossman, A.B., The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumors (2001) Ann Oncol, 12 (SUPPL. 2), pp. S47-S50
Kaltsas, G.A., Bessere, M., Grossman, A.B., The diagnosis and medical management of advanced neuroendocrine tumors (2004) Endocr Rev, 25, pp. 458-511
Rubin, J., Ajani, J., Schirmer, W., Octreatide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome (1999) J Clin Oncol, 17, pp. 600-606
Agarwal, S.K., Kester, M.B., Debelenko, L.V., Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states (1997) Hum Mol Genet, 6, pp. 1169-1175
Debelenko, L.V., Swalwell, Jl., Kelley, M.J., MEN 1 gene mutation analysis of high-grade neuroendocrine lung carcinoma (2000) Genes Chromosomes Cancer, 28, pp. 58-65
Hainsworth, H.D., Johnson, D.H., Greco, F.A., Poorly differentiated neuroendocrine carcinoma of unknown primary site: A newly recognized clinicopathologic entity (1988) Ann Int Med, 109, pp. 364-371
O'Toole, D., Maire, F., Ruszniewski, P., Ablative therapies for liver metastases of digestive endocrine tumors (2003) Endocr Relat Cancer, 10, pp. 463-468
La Rosa, S., Sessa, F., Capella, C., Prognostic criteria in nonfunctioning pancreatic endocrine tumors (1996) Virchows Arch, 429, pp. 323-333
Rindi, G., Azzoni, C., La Rosa, S., 1999 ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: Prognostic evaluation by pathological analysis (1999) Gastroenterology, 116, pp. 532-542
Oberg, K., Carcinoid tumors: Molecular genetics, tumor biology, and update of diagnosis and treatment (2002) Curr Opin Oncol, 14, pp. 38-45
Barakat, M.T., Meeran, K., Bloom, S.R., Neuroendocrine tumors (2004) Endocr Relat Cancer, 11, pp. 1-18
Norton, J.A., Fraker, D.L., Alexander, H.R., Surgery to cure the Zollinger-Ellison syndrome (1999) N Engl J Med, 341, pp. 635-644
Moertel, C.G., Knolsk, L.K., O'Connell, M.J., Rubin, J., Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms (1991) Cancer, 68, pp. 227-232
Mitry, E., Baudin, E., Ducreaux, M., Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin (1999) Br J Cancer, 81, pp. 1351-1355
Fjallskog, M.L., Granberg, D.P., Welin, S.L., Treatment with cisplatin and etoposide in patients with neuroendocrine tumors (2001) Cancer, 92, pp. 1101-1107
Ducreux, M., Baudin, E., Schlumberger, M., Treatment strategy of neuroendocrine tumors (2002) Rev Prat, 52, pp. 290-296
Ferjoux, G., Torrisani, J., Buscail, L., Pradayrol, L., Susini, C., Somatostatin receptors and cancer: Antioncogenic role of sst2A (2002) The Expanding Role of Octreotide I: Advances in Oncology, pp. 3-15. , SWJ Lamberts and L Dogliotti eds. Bristol: BioScientifica Ltd
Lamberts, S.W.J., Krenning, E.P., Reubi, J.C., The role of somatostatin and its analogs in the diagnosis and treatment of tumors (1991) Endocr Rev, 12, pp. 450-482
Kwekkeboom, D.J., Krenning, E.P., Somatostatin receptors imaging (2002) The Expanding Role of Octreotide I: Advances in Oncology, pp. 17-30. , SWJ Lamberts and L Dogliotti eds. Bristol: BioScientifica Ltd
Shi, W., Buchanan, K.D., Johnston, C.F., The octreoscan suppression test and [111In-DTPA-D-Phe 1]-octreotide scintigraphy in neuroendocrine tumors correlate with responsiveness to somatostatin analogue treatment (1998) Clin Endocrinol (Oxf), 48, pp. 303-309
Oberg, K., Chemotherapy and biotherapy in the treatment of neuroendocrine tumors (2001) Ann Oncol, 12 S2, pp. S111-S114
Aparicio, T., Ducreux, M., Baudin, E., Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumors (2001) Eur J Cancer, 37, pp. 1014-1019
Dejong, C.H., Parks, R.W., Currie, E., Piris, J., Redhead, D.N., Garden, O.J., Treatment of hepatic metastases of neuroendocrine malignancies: A 10-year experience (2002) J R Coll Surg Edinb, 47, pp. 495-499
Dogliotti, L., Brizzi, M.P., Berruti, A., A new approach in the medical treatment of neuroendocrine tumors - 5-fluorouracil continuous infusion plus octreotide-LAR: A feasibility study (2002) The Expanding Role of Octreotide I: Advances in Oncology, pp. 81-88. , SW Lamberts and Dogliotti eds. Bristol: BioScientifica Ltd
Kulke, M. H., Mayer, R. J., Carcinoid tumors (1999) N Engl J Med, 340, pp. 858-86
Modlin, I. M., Sandor, A., An analysis of 8305 cases of carcinoid tumors (1997) Cancer, 79, pp. 813-818
Levi, F., Te, V. C., Randimbision, L., Rindi, G., La Vecchia, C., Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97 (2000) Br J Cancer, 83, pp. 952-955
G trtz, B., Roth, J., Krahenmann, A., Mutations and allelic deletions of the MEN 1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms (1999) Am J Pathol, 154, pp. 429-436
Muligan, L. M., Kwok, J. B., Healey, C. S., Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (1993) Nature, 363, pp. 458-460
Vortmeyer, A. O., Lubensky, I. A., Erino, M. J., Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas (1997) J Nat Cancer Lnst, 89, pp. 1448-1453
Solcia, E., Kl ppel, G., Sobin, L. H., World Health Organization International Histological Classification of tumors (2000) Histological Typing of Neuroendocrine Tumors. 2nd Ed, pp. 1-5. , Berlin, Heidelberg: Springer-Verlag
Ardill, J. E. S., Erikkson, B., The importance of the measurement of circulationg markers in patients with neuroendocrine tumors of the pancreas and gut (2003) Endocr Relat Cancer, 10, pp. 459-462
Kaltsas, G. A., Mukherjee, J. J., Gossman, A. B., The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumors (2001) Ann Oncol, 12 (SUPPL. 2), pp. S47-S50
Kaltsas, G. A., Bessere, M., Grossman, A. B., The diagnosis and medical management of advanced neuroendocrine tumors (2004) Endocr Rev, 25, pp. 458-511
Agarwal, S. K., Kester, M. B., Debelenko, L. V., Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states (1997) Hum Mol Genet, 6, pp. 1169-1175
Debelenko, L. V., Swalwell, Jl., Kelley, M. J., MEN 1 gene mutation analysis of high-grade neuroendocrine lung carcinoma (2000) Genes Chromosomes Cancer, 28, pp. 58-65
Hainsworth, H. D., Johnson, D. H., Greco, F. A., Poorly differentiated neuroendocrine carcinoma of unknown primary site: A newly recognized clinicopathologic entity (1988) Ann Int Med, 109, pp. 364-371
Barakat, M. T., Meeran, K., Bloom, S. R., Neuroendocrine tumors (2004) Endocr Relat Cancer, 11, pp. 1-18
Norton, J. A., Fraker, D. L., Alexander, H. R., Surgery to cure the Zollinger-Ellison syndrome (1999) N Engl J Med, 341, pp. 635-644
Moertel, C. G., Knolsk, L. K., O'Connell, M. J., Rubin, J., Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms (1991) Cancer, 68, pp. 227-232
Fjallskog, M. L., Granberg, D. P., Welin, S. L., Treatment with cisplatin and etoposide in patients with neuroendocrine tumors (2001) Cancer, 92, pp. 1101-1107
Lamberts, S. W. J., Krenning, E. P., Reubi, J. C., The role of somatostatin and its analogs in the diagnosis and treatment of tumors (1991) Endocr Rev, 12, pp. 450-482
Kwekkeboom, D. J., Krenning, E. P., Somatostatin receptors imaging (2002) The Expanding Role of Octreotide I: Advances in Oncology, pp. 17-30. , SWJ Lamberts and L Dogliotti eds. Bristol: BioScientifica Ltd
Dejong, C. H., Parks, R. W., Currie, E., Piris, J., Redhead, D. N., Garden, O. J., Treatment of hepatic metastases of neuroendocrine malignancies: A 10-year experience (2002) J R Coll Surg Edinb, 47, pp. 495-499
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2005 Apr; 28(4): 371-378.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 1.496, 5-year impact factor: 1.273
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-23344454963&partnerID=40&md5=984ec2eb70e02d812cc69aa5a2a25691
Keywords: Nse, Octreoscan, Octreotide Lar, Ovarian Carcinoma, Poorly Differentiated Neuroendocrine Carcinoma, Thyroid Carcinoma, Cisplatin, Etoposide, Antineoplastic Agent, Antineoplastic Hormone Agonists And Antagonists, Article, Case Report, Clinical Feature, Dyspnea, Endocrine Gland, Female, Goiter, Histology, Human, Human Tissue, Immunohistochemistry, Liver Metastasis, Liver Polycystic Disease, Lymph Node, Neuroendocrine Tumor, Pericardium, Small Cell Carcinoma, Thyroid Nodule, Trachea Muscle, Tumor Differentiation, Tumor Localization, Adrenal Tumor, Liver Tumor, Lymph Node Metastasis, Ovary Tumor, Pathology, Treatment Outcome, Adrenal Gland Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Liver Neoplasms, Lymphatic Metastasis, Unknown Primary, Ovarian Neoplasms,
Affiliations:
*** IBB - CNR ***
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
Department of Anatomical Pathology and Cytology, Federico II University of Naples, Naples, Italy
Department of Biomorphological and Functional Sciences, Federico II University of Naples, Naples, Italy
References:
Kulke, M.H., Mayer, R.J., Carcinoid tumors (1999) N Engl J Med, 340, pp. 858-86
Modlin, I.M., Sandor, A., An analysis of 8305 cases of carcinoid tumors (1997) Cancer, 79, pp. 813-818
Levi, F., Te, V.C., Randimbision, L., Rindi, G., La Vecchia, C., Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97 (2000) Br J Cancer, 83, pp. 952-955
Soga, J., Statistical evaluation of 2001 carcinoid cases with metastases, collected from literature: A comparative study between ordinary carcinoids and atypical varieties (1998) J Exp Clin Cancer Res, 17, pp. 3-12
Götrtz, B., Roth, J., Krahenmann, A., Mutations and allelic deletions of the MEN 1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms (1999) Am J Pathol, 154, pp. 429-436
Lohmann, D., Putz, B., Reich, U., Bohm, J., Prauer, H., Hofler, H., Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data (1993) Am J Pathol, 142, pp. 907-915
Muligan, L.M., Kwok, J.B., Healey, C.S., Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (1993) Nature, 363, pp. 458-460
Vortmeyer, A.O., Lubensky, I.A., Erino, M.J., Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas (1997) J Nat Cancer Lnst, 89, pp. 1448-1453
Solda, E., Cappella, C., Fiocca, R., Sessa, F., La Rosa, S., Rindi, G., Disorders of the endocrine system (1998) Pathology of the Gastrointestinal Tract, HGSC Ming, pp. 295-322. , Williams & Wilkins eds. Philadelphia
Solcia, E., Klöppel, G., Sobin, L.H., World Health Organization International Histological Classification of tumors (2000) Histological Typing of Neuroendocrine Tumors. 2nd Ed, pp. 1-5. , Berlin, Heidelberg: Springer-Verlag
Mitry, E., Rougier, R., The treatment of undifferentiated neuroendocrine tumors (2001) Crit Rev Oncol Hematol, 37, pp. 47-51
Ardill, J.E.S., Erikkson, B., The importance of the measurement of circulationg markers in patients with neuroendocrine tumors of the pancreas and gut (2003) Endocr Relat Cancer, 10, pp. 459-462
Caplin, M., Wiedenmann, B., The management of patients with neuroendocrine tumors (2003) Endocr Relat Cancer, 10, pp. 425-426
Kaltsas, G.A., Mukherjee, J.J., Gossman, A.B., The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumors (2001) Ann Oncol, 12 (SUPPL. 2), pp. S47-S50
Kaltsas, G.A., Bessere, M., Grossman, A.B., The diagnosis and medical management of advanced neuroendocrine tumors (2004) Endocr Rev, 25, pp. 458-511
Rubin, J., Ajani, J., Schirmer, W., Octreatide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome (1999) J Clin Oncol, 17, pp. 600-606
Agarwal, S.K., Kester, M.B., Debelenko, L.V., Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states (1997) Hum Mol Genet, 6, pp. 1169-1175
Debelenko, L.V., Swalwell, Jl., Kelley, M.J., MEN 1 gene mutation analysis of high-grade neuroendocrine lung carcinoma (2000) Genes Chromosomes Cancer, 28, pp. 58-65
Hainsworth, H.D., Johnson, D.H., Greco, F.A., Poorly differentiated neuroendocrine carcinoma of unknown primary site: A newly recognized clinicopathologic entity (1988) Ann Int Med, 109, pp. 364-371
O'Toole, D., Maire, F., Ruszniewski, P., Ablative therapies for liver metastases of digestive endocrine tumors (2003) Endocr Relat Cancer, 10, pp. 463-468
La Rosa, S., Sessa, F., Capella, C., Prognostic criteria in nonfunctioning pancreatic endocrine tumors (1996) Virchows Arch, 429, pp. 323-333
Rindi, G., Azzoni, C., La Rosa, S., 1999 ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: Prognostic evaluation by pathological analysis (1999) Gastroenterology, 116, pp. 532-542
Oberg, K., Carcinoid tumors: Molecular genetics, tumor biology, and update of diagnosis and treatment (2002) Curr Opin Oncol, 14, pp. 38-45
Barakat, M.T., Meeran, K., Bloom, S.R., Neuroendocrine tumors (2004) Endocr Relat Cancer, 11, pp. 1-18
Norton, J.A., Fraker, D.L., Alexander, H.R., Surgery to cure the Zollinger-Ellison syndrome (1999) N Engl J Med, 341, pp. 635-644
Moertel, C.G., Knolsk, L.K., O'Connell, M.J., Rubin, J., Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms (1991) Cancer, 68, pp. 227-232
Mitry, E., Baudin, E., Ducreaux, M., Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin (1999) Br J Cancer, 81, pp. 1351-1355
Fjallskog, M.L., Granberg, D.P., Welin, S.L., Treatment with cisplatin and etoposide in patients with neuroendocrine tumors (2001) Cancer, 92, pp. 1101-1107
Ducreux, M., Baudin, E., Schlumberger, M., Treatment strategy of neuroendocrine tumors (2002) Rev Prat, 52, pp. 290-296
Ferjoux, G., Torrisani, J., Buscail, L., Pradayrol, L., Susini, C., Somatostatin receptors and cancer: Antioncogenic role of sst2A (2002) The Expanding Role of Octreotide I: Advances in Oncology, pp. 3-15. , SWJ Lamberts and L Dogliotti eds. Bristol: BioScientifica Ltd
Lamberts, S.W.J., Krenning, E.P., Reubi, J.C., The role of somatostatin and its analogs in the diagnosis and treatment of tumors (1991) Endocr Rev, 12, pp. 450-482
Kwekkeboom, D.J., Krenning, E.P., Somatostatin receptors imaging (2002) The Expanding Role of Octreotide I: Advances in Oncology, pp. 17-30. , SWJ Lamberts and L Dogliotti eds. Bristol: BioScientifica Ltd
Shi, W., Buchanan, K.D., Johnston, C.F., The octreoscan suppression test and [111In-DTPA-D-Phe 1]-octreotide scintigraphy in neuroendocrine tumors correlate with responsiveness to somatostatin analogue treatment (1998) Clin Endocrinol (Oxf), 48, pp. 303-309
Oberg, K., Chemotherapy and biotherapy in the treatment of neuroendocrine tumors (2001) Ann Oncol, 12 S2, pp. S111-S114
Aparicio, T., Ducreux, M., Baudin, E., Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumors (2001) Eur J Cancer, 37, pp. 1014-1019
Dejong, C.H., Parks, R.W., Currie, E., Piris, J., Redhead, D.N., Garden, O.J., Treatment of hepatic metastases of neuroendocrine malignancies: A 10-year experience (2002) J R Coll Surg Edinb, 47, pp. 495-499
Dogliotti, L., Brizzi, M.P., Berruti, A., A new approach in the medical treatment of neuroendocrine tumors - 5-fluorouracil continuous infusion plus octreotide-LAR: A feasibility study (2002) The Expanding Role of Octreotide I: Advances in Oncology, pp. 81-88. , SW Lamberts and Dogliotti eds. Bristol: BioScientifica Ltd
Kulke, M. H., Mayer, R. J., Carcinoid tumors (1999) N Engl J Med, 340, pp. 858-86
Modlin, I. M., Sandor, A., An analysis of 8305 cases of carcinoid tumors (1997) Cancer, 79, pp. 813-818
Levi, F., Te, V. C., Randimbision, L., Rindi, G., La Vecchia, C., Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97 (2000) Br J Cancer, 83, pp. 952-955
G trtz, B., Roth, J., Krahenmann, A., Mutations and allelic deletions of the MEN 1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms (1999) Am J Pathol, 154, pp. 429-436
Muligan, L. M., Kwok, J. B., Healey, C. S., Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (1993) Nature, 363, pp. 458-460
Vortmeyer, A. O., Lubensky, I. A., Erino, M. J., Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas (1997) J Nat Cancer Lnst, 89, pp. 1448-1453
Solcia, E., Kl ppel, G., Sobin, L. H., World Health Organization International Histological Classification of tumors (2000) Histological Typing of Neuroendocrine Tumors. 2nd Ed, pp. 1-5. , Berlin, Heidelberg: Springer-Verlag
Ardill, J. E. S., Erikkson, B., The importance of the measurement of circulationg markers in patients with neuroendocrine tumors of the pancreas and gut (2003) Endocr Relat Cancer, 10, pp. 459-462
Kaltsas, G. A., Mukherjee, J. J., Gossman, A. B., The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumors (2001) Ann Oncol, 12 (SUPPL. 2), pp. S47-S50
Kaltsas, G. A., Bessere, M., Grossman, A. B., The diagnosis and medical management of advanced neuroendocrine tumors (2004) Endocr Rev, 25, pp. 458-511
Agarwal, S. K., Kester, M. B., Debelenko, L. V., Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states (1997) Hum Mol Genet, 6, pp. 1169-1175
Debelenko, L. V., Swalwell, Jl., Kelley, M. J., MEN 1 gene mutation analysis of high-grade neuroendocrine lung carcinoma (2000) Genes Chromosomes Cancer, 28, pp. 58-65
Hainsworth, H. D., Johnson, D. H., Greco, F. A., Poorly differentiated neuroendocrine carcinoma of unknown primary site: A newly recognized clinicopathologic entity (1988) Ann Int Med, 109, pp. 364-371
Barakat, M. T., Meeran, K., Bloom, S. R., Neuroendocrine tumors (2004) Endocr Relat Cancer, 11, pp. 1-18
Norton, J. A., Fraker, D. L., Alexander, H. R., Surgery to cure the Zollinger-Ellison syndrome (1999) N Engl J Med, 341, pp. 635-644
Moertel, C. G., Knolsk, L. K., O'Connell, M. J., Rubin, J., Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms (1991) Cancer, 68, pp. 227-232
Fjallskog, M. L., Granberg, D. P., Welin, S. L., Treatment with cisplatin and etoposide in patients with neuroendocrine tumors (2001) Cancer, 92, pp. 1101-1107
Lamberts, S. W. J., Krenning, E. P., Reubi, J. C., The role of somatostatin and its analogs in the diagnosis and treatment of tumors (1991) Endocr Rev, 12, pp. 450-482
Kwekkeboom, D. J., Krenning, E. P., Somatostatin receptors imaging (2002) The Expanding Role of Octreotide I: Advances in Oncology, pp. 17-30. , SWJ Lamberts and L Dogliotti eds. Bristol: BioScientifica Ltd
Dejong, C. H., Parks, R. W., Currie, E., Piris, J., Redhead, D. N., Garden, O. J., Treatment of hepatic metastases of neuroendocrine malignancies: A 10-year experience (2002) J R Coll Surg Edinb, 47, pp. 495-499
Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: Response to chemotherapy and octreotide LAR
Neuroendocrine tumors represent a heterogeneous category of neoplasm, with conflicting diagnostic and therapeutic demands. We here describe the case of a 72-yr-old woman with evidence of a poorly differentiated small-cell neuroendocrine carcinoma (NEC) localized in different endocrine glands and other non-endocrine organs. In particular, a large ovarian mass, multinodular thyroid goiter, right adrenal mass, cystic liver metastases and anterior mediastinum lymph node metastasis were present. The largest thyroid nodule caused tracheal restriction and dyspnea. Diagnosis of poorly differentiated metastasized NEC of unknown origin was made on the basis of histological and immunohistochemical findings, and treatment with etoposide (1100 mg/m(2) in days 1, 2 and 3) and cisplatinum (45 mg/m(2) in days 2 and 3) was initiated. Simultaneously, im administration of octreotide LAR 20 mg every 28 days was started, according to the presence of SS receptors at In-111-octreotide scan. Rapid improvement of dyspnea and a reduction of the largest thyroid nodule, liver metastases and adrenal mass by 50% were observed after 3 months of treatment; the dimensions remained stable thereafter, while the pericardial lymph node disappeared. In conclusion, poorly differentiated NEC of unknown primary site is a well-recognized category, usually with an aggressive behavior, rapid growth rate and wide dissemination. Median survival of these patients is 6 months if left untreated. Our patient is alive 18 months after beginning the treatment, reporting good general condition and quality of life over the whole follow-up period. (c) 2005, Editrice Kurtis.
Neuroendocrine tumors represent a heterogeneous category of neoplasm, with conflicting diagnostic and therapeutic demands. We here describe the case of a 72-yr-old woman with evidence of a poorly differentiated small-cell neuroendocrine carcinoma (NEC) localized in different endocrine glands and other non-endocrine organs. In particular, a large ovarian mass, multinodular thyroid goiter, right adrenal mass, cystic liver metastases and anterior mediastinum lymph node metastasis were present. The largest thyroid nodule caused tracheal restriction and dyspnea. Diagnosis of poorly differentiated metastasized NEC of unknown origin was made on the basis of histological and immunohistochemical findings, and treatment with etoposide (1100 mg/m(2) in days 1, 2 and 3) and cisplatinum (45 mg/m(2) in days 2 and 3) was initiated. Simultaneously, im administration of octreotide LAR 20 mg every 28 days was started, according to the presence of SS receptors at In-111-octreotide scan. Rapid improvement of dyspnea and a reduction of the largest thyroid nodule, liver metastases and adrenal mass by 50% were observed after 3 months of treatment; the dimensions remained stable thereafter, while the pericardial lymph node disappeared. In conclusion, poorly differentiated NEC of unknown primary site is a well-recognized category, usually with an aggressive behavior, rapid growth rate and wide dissemination. Median survival of these patients is 6 months if left untreated. Our patient is alive 18 months after beginning the treatment, reporting good general condition and quality of life over the whole follow-up period. (c) 2005, Editrice Kurtis.
Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: Response to chemotherapy and octreotide LAR
| ▼ Clinical Oncology |
Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: Response to chemotherapy and octreotide LAR
Other filter: ([btitle,keywords] "Octreoscan" OR [btit ...
Orlandella FM, Mariniello RM, Iervolino PLC, Auletta L, De Stefano AE, Ugolini C, Greco A, Mirabelli P, Pane K, Franzese M, Denaro M, Basolo F, Salvatore G
* Junctional adhesion molecule-A is down-regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 alpha/beta pathways (205 views)
Mol Carcinog (ISSN: 0899-1987linking), 2019 Mar 4; 58(7): 1181-1193.
Impact Factor: 3.851
View Export to BibTeX Export to EndNote
Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R
* Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience (407 views)
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2017 Nov 06; 59(1): 90-101.
Impact Factor: 3.179
View Export to BibTeX Export to EndNote
Russo M, Malandrino P, Moleti M, Vermiglio F, Violi MA, Marturano I, Minaldi E, Vigneri R, Pellegriti G, Regalbuto C
* Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods (269 views)
J Endocrinol Invest (ISSN: 1720-8386, 0391-4097, 1720-8386electronic), 2017 May 20; 40(11): 1235-1241.
Impact Factor: 3.166
View Export to BibTeX Export to EndNote
Greco A, Albanese S, Auletta L, Mirabelli P, Zannetti A, D'Alterio C, Di Maro G, Orlandella FM, Salvatore G, Soricelli A, Salvatore M
* High-frequency ultrasound-guided injection for the generation of a novel orthotopic mouse model of human thyroid carcinoma (493 views)
Thyroid (ISSN: 1050-7256, 1050-7256linking), 2016 Feb 4; 26(4): 552-558.
Impact Factor: 5.515
View Export to BibTeX Export to EndNote
De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S
* Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma (332 views)
Ann Nucl Med (ISSN: 0914-7187, 1864-6433, 0914-7187linking), 2016 Jan 11; 30(3): 1-8.
Impact Factor: 1.396
View Export to BibTeX Export to EndNote
Albanese S, Auletta L, Zannetti A, Di Maro G, Mirabelli P, D'Alterio C, Salvatore G, Soricelli A, Salvatore M, Greco A
* High Frequency Ultrasound for the development of an Orthotopic mouse model of Human Follicular Thyroid Carcinoma (371 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2015; 42: S416-S416.
Impact Factor: 5.537
View Export to BibTeX Export to EndNote
Insabato L, Natella V, Somma A, Persico M, Camera L, Losito NS, Masone S
* Primary Peritoneal Clear Cell Carcinoma Versus Ovarian Carcinoma Versus Malignant Transformation of Endometriosis: A Vexing Issue (300 views)
Int J Surg Pathol (ISSN: 1066-8969), 2015; 23(3): 211-216.
Impact Factor: 0.782
View Export to BibTeX Export to EndNote
Formicola F, Riccardi A, Vigliar E, Biondi B, Accurso A, Del Vecchio W, Imbriaco M
* Multimetastatic medullary thyroid carcinoma to the breast: PET/CT--mammographic-US and MR findings (262 views)
Breast J (ISSN: 1075-122x), 2014 Nov; 20(6): 653-654.
Impact Factor: 1.411
View Export to BibTeX Export to EndNote
Fonti R, Mainolfi C, Anzivino A, Camera L, Faggiano A, Colao A, Salvatore M, Del Vecchio S
* 18F-FDG-PET/CT and 111In-Octreotide SPECT in Patients with Metastatic Medullary Thyroid Carcinoma (270 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Gallicchio R, Giacomobono S, Capacchione D, Nardelli A, Barbato F, Nappi A, Pellegrino T, Storto G
* Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation? (430 views)
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2013 Oct; 44(2): 426-433.
Impact Factor: 3.527
View Export to BibTeX Export to EndNote
Passaro C, Abagnale A, Libertini S, Volpe M, Botta G, Cella L, Pacelli R, Halldèn G, Gillespie D, Portella G
* Ionizing radiation enhances dl922-947-mediated cell death of anaplastic thyroid carcinoma cells (444 views)
Endocr Relat Cancerendocrine Related Cancer (ISSN: 1351-0088), 2013 Sep 19; 20(5): 633-647.
Impact Factor: 4.907
View Export to BibTeX Export to EndNote
D'Angelo D, Borbone E, Palmieri D, Uboldi S, Esposito F, Frapolli R, Pacelli R, D'Incalci M, Fusco A
* The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin (395 views)
European Journal Of Cancer (ISSN: 0959-8049), 2013 Mar; 49(5): 1142-1151.
Impact Factor: 4.819
View Export to BibTeX Export to EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (479 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Caleo O, Maurea S, Klain M, Salvatore B, Storto G, Mancini M, Pace L, Salvatore M
* Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: Comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose (287 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2009 Dec; 114(8): 1385-1385.
Impact Factor: 1.454
View Export to BibTeX Export to EndNote
Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M
* Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation (367 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2008 Mar; 52(1): 2-8.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Caleo O, Maurea S, Klain M, Salvatore B, Storto G, Mancini M, Pace L, Salvatore M
* Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: Comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose (299 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2008 Mar; 113(2): 278-288.
Impact Factor: 0.955
View Export to BibTeX Export to EndNote
Iommelli F, Zannetti A, Pepe S, Sabbatino F, Laus G, Ghidelli L, Solla R, Scala S, Del Vecchio S, Salvatore M, Pacelli R
* Inhibition of NF-kappa B activity potentiates ionizing radiation and cisplatin induced cell killing of anaplastic thyroid carcinoma cells (422 views)
Meetingproceedings Of The American Association For Cancer Research Annual (ISSN: 0197-016x), 2006 Apr; 47: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Pace L, Klain M, Albanese C, Salvatore B, Storto G, Soricelli A, Salvatore M
* Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment (396 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Feb; 33(2): 179-183.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Pace L, Klain M, Soricelli A, Albanese C, Salvatore B, Storto G, Salvatore M
* Short Term Outcome of Differentiated Thyroid Cancer Patients with Detectable Serum Thyroglobulin after Initial Treatment Receiving a Second 131-IODINE Therapy (334 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: 179-183.
Impact Factor: 3.883
View Export to BibTeX Export to EndNote
Cozzolino R, Palladino P, Rossi F, Cali G, Benedetti E, Laccetti P
* Antineoplastic cyclic astin analogues kill tumour cells via caspase-mediated induction of apoptosis (524 views)
Carcinogenesis (ISSN: 0143-3334), 2005 Apr; 26(4): 733-739.
Impact Factor: 5.108
View Export to BibTeX Export to EndNote
Portella G, Pacelli R, Libertini S, Cella L, Vecchio G, Salvatore M, Fusco A
* ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells (467 views)
J Clin Endocrinol Metab Journal Of Clinical Endocrinology And Metabolism (ISSN: 0021-972x), 2003 Oct 1; 88(10): 5027-5032.
Impact Factor: 5.873
View Export to BibTeX Export to EndNote
Spalletti-cernia D, Sorrentino R, Di Gaetano S, Arciello A, Garbi C, Piccoli R, D'Alessio G, Vecchio G, Laccetti P, Santoro M
* Antineoplastic ribonucleases selectively kill thyroid carcinoma cells via caspase-mediated induction of apoptosis (384 views)
Journal Of Clinical Endocrinology & Metabolism (ISSN: 0021-972x), 2003 Jun; 88(6): 2900-2907.
Impact Factor: 5.873
View Export to BibTeX Export to EndNote
Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas (387 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Impact Factor: 0.957
View Export to BibTeX Export to EndNote
Biondi B, Fazio S, Cuocolo A, Sabatini D, Nicolai E, Lombardi G, Salvatore M, Sacca L
Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine (336 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1996 Dec; 81(12): 4224-4228.
Impact Factor: 4.575
View Export to BibTeX Export to EndNote
Li PY, Del Vecchio S, Fonti R, Carriero MV, Potena MI, Botti G, Miotti S, Lastoria S, Menard S, Colnaghi MI, Salvatore M
Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography (450 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 Apr; 37(4-6): 665-672.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
Camera L, Del Vecchio S, Petrillo A, Esposito G, Frasci G, Iaffaioli RV, Bianco AR, Salvatore M
Evaluation of therapeutic response using iodine-131-B72. 3 monoclonal antibody in patients with ovarian carcinoma (463 views)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1991 Apr; 18(4): 269-273.
Impact Factor: 2.692
View Export to BibTeX Export to EndNote
* Junctional adhesion molecule-A is down-regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 alpha/beta pathways (205 views)
Mol Carcinog (ISSN: 0899-1987linking), 2019 Mar 4; 58(7): 1181-1193.
Impact Factor: 3.851
View Export to BibTeX Export to EndNote
Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R
* Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience (407 views)
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2017 Nov 06; 59(1): 90-101.
Impact Factor: 3.179
View Export to BibTeX Export to EndNote
Russo M, Malandrino P, Moleti M, Vermiglio F, Violi MA, Marturano I, Minaldi E, Vigneri R, Pellegriti G, Regalbuto C
* Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods (269 views)
J Endocrinol Invest (ISSN: 1720-8386, 0391-4097, 1720-8386electronic), 2017 May 20; 40(11): 1235-1241.
Impact Factor: 3.166
View Export to BibTeX Export to EndNote
Greco A, Albanese S, Auletta L, Mirabelli P, Zannetti A, D'Alterio C, Di Maro G, Orlandella FM, Salvatore G, Soricelli A, Salvatore M
* High-frequency ultrasound-guided injection for the generation of a novel orthotopic mouse model of human thyroid carcinoma (493 views)
Thyroid (ISSN: 1050-7256, 1050-7256linking), 2016 Feb 4; 26(4): 552-558.
Impact Factor: 5.515
View Export to BibTeX Export to EndNote
De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S
* Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma (332 views)
Ann Nucl Med (ISSN: 0914-7187, 1864-6433, 0914-7187linking), 2016 Jan 11; 30(3): 1-8.
Impact Factor: 1.396
View Export to BibTeX Export to EndNote
Albanese S, Auletta L, Zannetti A, Di Maro G, Mirabelli P, D'Alterio C, Salvatore G, Soricelli A, Salvatore M, Greco A
* High Frequency Ultrasound for the development of an Orthotopic mouse model of Human Follicular Thyroid Carcinoma (371 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2015; 42: S416-S416.
Impact Factor: 5.537
View Export to BibTeX Export to EndNote
Insabato L, Natella V, Somma A, Persico M, Camera L, Losito NS, Masone S
* Primary Peritoneal Clear Cell Carcinoma Versus Ovarian Carcinoma Versus Malignant Transformation of Endometriosis: A Vexing Issue (300 views)
Int J Surg Pathol (ISSN: 1066-8969), 2015; 23(3): 211-216.
Impact Factor: 0.782
View Export to BibTeX Export to EndNote
Formicola F, Riccardi A, Vigliar E, Biondi B, Accurso A, Del Vecchio W, Imbriaco M
* Multimetastatic medullary thyroid carcinoma to the breast: PET/CT--mammographic-US and MR findings (262 views)
Breast J (ISSN: 1075-122x), 2014 Nov; 20(6): 653-654.
Impact Factor: 1.411
View Export to BibTeX Export to EndNote
Fonti R, Mainolfi C, Anzivino A, Camera L, Faggiano A, Colao A, Salvatore M, Del Vecchio S
* 18F-FDG-PET/CT and 111In-Octreotide SPECT in Patients with Metastatic Medullary Thyroid Carcinoma (270 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Gallicchio R, Giacomobono S, Capacchione D, Nardelli A, Barbato F, Nappi A, Pellegrino T, Storto G
* Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation? (430 views)
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2013 Oct; 44(2): 426-433.
Impact Factor: 3.527
View Export to BibTeX Export to EndNote
Passaro C, Abagnale A, Libertini S, Volpe M, Botta G, Cella L, Pacelli R, Halldèn G, Gillespie D, Portella G
* Ionizing radiation enhances dl922-947-mediated cell death of anaplastic thyroid carcinoma cells (444 views)
Endocr Relat Cancerendocrine Related Cancer (ISSN: 1351-0088), 2013 Sep 19; 20(5): 633-647.
Impact Factor: 4.907
View Export to BibTeX Export to EndNote
D'Angelo D, Borbone E, Palmieri D, Uboldi S, Esposito F, Frapolli R, Pacelli R, D'Incalci M, Fusco A
* The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin (395 views)
European Journal Of Cancer (ISSN: 0959-8049), 2013 Mar; 49(5): 1142-1151.
Impact Factor: 4.819
View Export to BibTeX Export to EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (479 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Caleo O, Maurea S, Klain M, Salvatore B, Storto G, Mancini M, Pace L, Salvatore M
* Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: Comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose (287 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2009 Dec; 114(8): 1385-1385.
Impact Factor: 1.454
View Export to BibTeX Export to EndNote
Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M
* Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation (367 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2008 Mar; 52(1): 2-8.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Caleo O, Maurea S, Klain M, Salvatore B, Storto G, Mancini M, Pace L, Salvatore M
* Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: Comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose (299 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2008 Mar; 113(2): 278-288.
Impact Factor: 0.955
View Export to BibTeX Export to EndNote
Iommelli F, Zannetti A, Pepe S, Sabbatino F, Laus G, Ghidelli L, Solla R, Scala S, Del Vecchio S, Salvatore M, Pacelli R
* Inhibition of NF-kappa B activity potentiates ionizing radiation and cisplatin induced cell killing of anaplastic thyroid carcinoma cells (422 views)
Meetingproceedings Of The American Association For Cancer Research Annual (ISSN: 0197-016x), 2006 Apr; 47: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Pace L, Klain M, Albanese C, Salvatore B, Storto G, Soricelli A, Salvatore M
* Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment (396 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Feb; 33(2): 179-183.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Pace L, Klain M, Soricelli A, Albanese C, Salvatore B, Storto G, Salvatore M
* Short Term Outcome of Differentiated Thyroid Cancer Patients with Detectable Serum Thyroglobulin after Initial Treatment Receiving a Second 131-IODINE Therapy (334 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: 179-183.
Impact Factor: 3.883
View Export to BibTeX Export to EndNote
Cozzolino R, Palladino P, Rossi F, Cali G, Benedetti E, Laccetti P
* Antineoplastic cyclic astin analogues kill tumour cells via caspase-mediated induction of apoptosis (524 views)
Carcinogenesis (ISSN: 0143-3334), 2005 Apr; 26(4): 733-739.
Impact Factor: 5.108
View Export to BibTeX Export to EndNote
Portella G, Pacelli R, Libertini S, Cella L, Vecchio G, Salvatore M, Fusco A
* ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells (467 views)
J Clin Endocrinol Metab Journal Of Clinical Endocrinology And Metabolism (ISSN: 0021-972x), 2003 Oct 1; 88(10): 5027-5032.
Impact Factor: 5.873
View Export to BibTeX Export to EndNote
Spalletti-cernia D, Sorrentino R, Di Gaetano S, Arciello A, Garbi C, Piccoli R, D'Alessio G, Vecchio G, Laccetti P, Santoro M
* Antineoplastic ribonucleases selectively kill thyroid carcinoma cells via caspase-mediated induction of apoptosis (384 views)
Journal Of Clinical Endocrinology & Metabolism (ISSN: 0021-972x), 2003 Jun; 88(6): 2900-2907.
Impact Factor: 5.873
View Export to BibTeX Export to EndNote
Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas (387 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Impact Factor: 0.957
View Export to BibTeX Export to EndNote
Biondi B, Fazio S, Cuocolo A, Sabatini D, Nicolai E, Lombardi G, Salvatore M, Sacca L
Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine (336 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1996 Dec; 81(12): 4224-4228.
Impact Factor: 4.575
View Export to BibTeX Export to EndNote
Li PY, Del Vecchio S, Fonti R, Carriero MV, Potena MI, Botti G, Miotti S, Lastoria S, Menard S, Colnaghi MI, Salvatore M
Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography (450 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 Apr; 37(4-6): 665-672.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
Camera L, Del Vecchio S, Petrillo A, Esposito G, Frasci G, Iaffaioli RV, Bianco AR, Salvatore M
Evaluation of therapeutic response using iodine-131-B72. 3 monoclonal antibody in patients with ovarian carcinoma (463 views)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1991 Apr; 18(4): 269-273.
Impact Factor: 2.692
View Export to BibTeX Export to EndNote
26 Records (23 excluding Abstracts).
Total impact factor: 88.969 (82.298 excluding Abstracts).
Total 5 year impact factor: 82.641 (76.443 excluding Abstracts).
Total impact factor: 88.969 (82.298 excluding Abstracts).
Total 5 year impact factor: 82.641 (76.443 excluding Abstracts).
328 views. Last view on Saturday 14 January 2023, 19:40:09
ibb.cnr.it
